Citius Oncology, Inc. (CTOR): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of CTOR were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No CTOR insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CTOR short interest
Low short interest. 0.2% of CTOR shares are sold short: about 1 share in 461. Over the last 12 reports the number of shares short went down 58%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 201,913 CTOR shares were sold short, 0.2% of the shares outstanding, down 11.2% from the report before. At the average daily volume of 170,140 shares, buying them all back would take about 1.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 201,913 | 0.22% | -11% | 170,140 | 1.2 |
| Oct 15, 2026 | 227,455 | 0.24% | -21% | 84,753 | 2.7 |
| Sep 30, 2026 | 289,717 | 0.31% | -43% | 129,388 | 2.2 |
| Sep 15, 2026 | 509,543 | 0.55% | +9% | 73,934 | 6.9 |
| Aug 31, 2026 | 468,965 | 0.50% | +4% | 64,312 | 7.3 |
| Aug 14, 2026 | 452,413 | 0.49% | +13% | 194,984 | 2.3 |
| Jul 31, 2026 | 399,412 | 0.43% | +9% | 64,468 | 6.2 |
| Jul 15, 2026 | 365,150 | 0.39% | -19% | 44,211 | 8.3 |
| Jun 30, 2026 | 453,353 | 0.49% | -9% | 39,787 | 11.4 |
| Jun 15, 2026 | 497,356 | 0.53% | -21% | 77,996 | 6.4 |
| May 29, 2026 | 631,733 | 0.68% | +30% | 65,907 | 9.6 |
| May 15, 2026 | 484,262 | 0.52% | -26% | 108,400 | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Citius Oncology company events
Citius Oncology filed 19 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Nov 4, 2026.
- Nov 4, 2026AnnouncementCitius Oncology, Inc. issued a press release announcing health-related quality of life results from pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma, presented at the European Organisation for Research and Treatment of Cancer… Filing
- Oct 26, 2026ResultsReleased financial results. Filing
- Oct 23, 2026AnnouncementCitius Oncology, Inc. received formal notice that the Nasdaq Stock Market LLC granted its request for an extension through April 19, 2027 to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Filing
- Sep 29, 2026VoteReported shareholder vote results. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 12, 2026LeadershipThe Board of Directors of Citius Oncology, Inc. expanded the number of directors serving on the Board to nine individuals and appointed Jonathan Peri, Ph.D., J.D. as a Class I member of the Board, effective August 10, 2026, to serve until the Company’s 2028 annual meeting of stockholders or until… Filing
- Aug 5, 2026AnnouncementCitius Oncology, Inc. issued a press release announcing an update on the expanding base of institutional accounts ordering LYMPHIR ® . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
- Jun 1, 2026AnnouncementCitius Oncology, Inc. issued a press release announcing the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology. Filing
- May 15, 2026ResultsReleased financial results. Filing
- May 6, 2026AgreementCitius Oncology, Inc., entered into a warrant inducement agreement with the holder of certain existing warrants to purchase up to an aggregate of 12,777,778 shares of the Company’s common stock, which consists of all of the 6,818,182 shares underlying warrants originally issued on July 16, 2025… Filing
- Apr 29, 2026AnnouncementCitius Oncology, Inc. issued a press release announcing the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners. Filing
- Apr 28, 2026ListingNasdaq Stock Market LLC notified Citius Oncology, Inc. that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Filing
- Mar 31, 2026AnnouncementWe issued a press release announcing a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl). Filing
- Mar 10, 2026AnnouncementWe issued a press release announcing positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators. Filing
- Mar 4, 2026AnnouncementWe issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse… Filing
- Feb 13, 2026ResultsReleased financial results. Filing
- Dec 23, 2025ResultsReleased financial results. Filing
- Dec 10, 2025AgreementCitius Oncology, Inc. entered into a securities purchase agreement with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock, $0.0001 par value per share, at an offering price of $1.09 per share of common stock. Filing
- Dec 1, 2025AnnouncementThe Company issued a press release announcing the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl), a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold CTOR
1 of the 50 well-known investors we track reported holding CTOR in their latest 13F filing. The largest position is Ken Griffin's, worth $127K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 125,822 | $127K | 0.0% | +39% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CTOR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
Questions about Citius Oncology, Inc. (CTOR) stock
Are CTOR insiders buying or selling?
No CTOR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in CTOR?
As of Oct 30, 2026, 201,913 CTOR shares were sold short, 0.2% of the shares outstanding, down 11.2% from the report before. At the average daily volume of 170,140 shares, buying them all back would take about 1.2 trading days (days to cover). See the history.
Which famous investors hold CTOR?
1 of the 50 well-known investors we track reported CTOR in their latest 13F filing, including Ken Griffin. The largest position is worth $127K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.